Literature DB >> 29769261

Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations.

Stefan O Ciurea1, Abhishek Chilkulwar1, Rima M Saliba1, Julianne Chen1, Gabriela Rondon1, Keyur P Patel2, Haitham Khogeer2, Abdul R Shah1, Brion V Randolph1, Jorge M Ramos Perez1, Uday Popat1, Chitra M Hosing1, Qaiser Bashir1, Rohtesh Mehta1, Gheath Al-Atrash1, Jin Im1, Issa F Khouri1, Partow Kebriaei1, Richard E Champlin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29769261      PMCID： PMC7218750          DOI： 10.1182/blood-2018-02-832360

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  16 in total

1.  TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis.

Authors:  D Bowen; M J Groves; A K Burnett; Y Patel; C Allen; C Green; R E Gale; R Hills; D C Linch
Journal:  Leukemia       Date:  2008-07-03       Impact factor: 11.528

2.  Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation.

Authors:  M Kim; S-A Yahng; A Kwon; J Park; Y-W Jeon; J-H Yoon; S-H Shin; S-E Lee; B-S Cho; K-S Eom; S Lee; C-K Min; H-J Kim; S-G Cho; D-W Kim; J-W Lee; W-S Min; S-H Lee; Y-J Kim
Journal:  Bone Marrow Transplant       Date:  2015-05-11       Impact factor: 5.483

3.  Mutations of the P53 gene in acute myeloid leukaemia.

Authors:  P Fenaux; C Preudhomme; I Quiquandon; P Jonveaux; J L Laï; M Vanrumbeke; M H Loucheux-Lefebvre; F Bauters; R Berger; J P Kerckaert
Journal:  Br J Haematol       Date:  1992-02       Impact factor: 6.998

4.  Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

Authors:  R Coleman Lindsley; Wael Saber; Brenton G Mar; Robert Redd; Tao Wang; Michael D Haagenson; Peter V Grauman; Zhen-Huan Hu; Stephen R Spellman; Stephanie J Lee; Michael R Verneris; Katharine Hsu; Katharina Fleischhauer; Corey Cutler; Joseph H Antin; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2017-02-09       Impact factor: 91.245

5.  Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A.

Authors:  Richard F Schlenk; Konstanze Döhner; Silja Mack; Michael Stoppel; Franz Király; Katharina Götze; Frank Hartmann; Heinz A Horst; Elisabeth Koller; Andreas Petzer; Wolfgang Grimminger; Guido Kobbe; Axel Glasmacher; Hans Salwender; Heinz Kirchen; Detlef Haase; Stephan Kremers; Axel Matzdorff; Axel Benner; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2010-08-30       Impact factor: 44.544

6.  Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.

Authors:  F Baron; M Labopin; D Niederwieser; S Vigouroux; J J Cornelissen; C Malm; L L Vindelov; D Blaise; J J W M Janssen; E Petersen; G Socié; A Nagler; V Rocha; M Mohty
Journal:  Leukemia       Date:  2012-05-22       Impact factor: 11.528

7.  TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.

Authors:  Tapan M Kadia; Preetesh Jain; Farhad Ravandi; Guillermo Garcia-Manero; Michael Andreef; Koichi Takahashi; Gautam Borthakur; Elias Jabbour; Marina Konopleva; Naval G Daver; Courtney Dinardo; Sherry Pierce; Rashmi Kanagal-Shamanna; Keyur Patel; Zeev Estrov; Jorge Cortes; Hagop M Kantarjian
Journal:  Cancer       Date:  2016-07-26       Impact factor: 6.860

8.  The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia.

Authors:  H Seifert; B Mohr; C Thiede; U Oelschlägel; U Schäkel; T Illmer; S Soucek; G Ehninger; M Schaich
Journal:  Leukemia       Date:  2009-01-08       Impact factor: 11.528

9.  Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.

Authors:  Matteo G Della Porta; Anna Gallì; Andrea Bacigalupo; Silvia Zibellini; Massimo Bernardi; Ettore Rizzo; Bernardino Allione; Maria Teresa van Lint; Pietro Pioltelli; Paola Marenco; Alberto Bosi; Maria Teresa Voso; Simona Sica; Mariella Cuzzola; Emanuele Angelucci; Marianna Rossi; Marta Ubezio; Alberto Malovini; Ivan Limongelli; Virginia V Ferretti; Orietta Spinelli; Cristina Tresoldi; Sarah Pozzi; Silvia Luchetti; Laura Pezzetti; Silvia Catricalà; Chiara Milanesi; Alberto Riva; Benedetto Bruno; Fabio Ciceri; Francesca Bonifazi; Riccardo Bellazzi; Elli Papaemmanuil; Armando Santoro; Emilio P Alessandrino; Alessandro Rambaldi; Mario Cazzola
Journal:  J Clin Oncol       Date:  2016-10-20       Impact factor: 44.544

10.  Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.

Authors:  Ibrahim Aldoss; Anh Pham; Sierra Min Li; Ketevan Gendzekhadze; Michelle Afkhami; Milhan Telatar; Hao Hong; Abbas Padeganeh; Victoria Bedell; Thai Cao; Samer K Khaled; Monzr M Al Malki; Amandeep Salhotra; Haris Ali; Ahmed Aribi; Joycelynne Palmer; Patricia Aoun; Ricardo Spielberger; Anthony S Stein; David Snyder; Margaret R O'Donnell; Joyce Murata-Collins; David Senitzer; Dennis Weisenburger; Stephen J Forman; Vinod Pullarkat; Guido Marcucci; Raju Pillai; Ryotaro Nakamura
Journal:  Haematologica       Date:  2017-09-29       Impact factor: 9.941
View more
  17 in total

1.  Allogeneic Hematopoietic Cell Transplantation in Younger Patients With Acute Myeloid Leukemia.

Authors:  Vijaya Raj Bhatt
Journal:  J Oncol Pract       Date:  2019-06       Impact factor: 3.840

Review 2.  Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.

Authors:  Courtney DiNardo; Curtis Lachowiez
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

Review 3.  Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.

Authors:  Helen E Heslop; Edward A Stadtmauer; John E Levine; Karen K Ballen; Yi-Bin Chen; Amy E DeZern; Mary Eapen; Mehdi Hamadani; Betty K Hamilton; Parameswaran Hari; Richard J Jones; Brent R Logan; Leslie S Kean; Eric S Leifer; Frederick L Locke; Richard T Maziarz; Eneida R Nemecek; Marcelo Pasquini; Rachel Phelan; Marcie L Riches; Bronwen E Shaw; Mark C Walters; Amy Foley; Steven M Devine; Mary M Horowitz
Journal:  Transplant Cell Ther       Date:  2021-08-27

4.  Quantification of mutant-allele expression at isoform level in cancer from RNA-seq data.

Authors:  Wenjiang Deng; Tian Mou; Yudi Pawitan; Trung Nghia Vu
Journal:  NAR Genom Bioinform       Date:  2022-07-13

5.  TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.

Authors:  Jayakumar Vadakekolathu; Catherine Lai; Stephen Reeder; Sarah E Church; Tressa Hood; Anbarasu Lourdusamy; Michael P Rettig; Ibrahim Aldoss; Anjali S Advani; John Godwin; Matthew J Wieduwilt; Martha Arellano; John Muth; Tung On Yau; Farhad Ravandi; Kendra Sweet; Heidi Altmann; Gemma A Foulds; Friedrich Stölzel; Jan Moritz Middeke; Marilena Ciciarello; Antonio Curti; Peter J M Valk; Bob Löwenberg; Ivana Gojo; Martin Bornhäuser; John F DiPersio; Jan K Davidson-Moncada; Sergio Rutella
Journal:  Blood Adv       Date:  2020-10-27

6.  Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.

Authors:  Jan Philipp Bewersdorf; Rory M Shallis; Lohith Gowda; Wei Wei; Karl Hager; Iris Isufi; Tae Kon Kim; Manoj M Pillai; Stuart Seropian; Nikolai A Podoltsev; Steven D Gore; Alexa J Siddon; Amer M Zeidan
Journal:  Leuk Lymphoma       Date:  2020-05-02

Review 7.  Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia.

Authors:  Alexandra Higgins; Mithun Vinod Shah
Journal:  Genes (Basel)       Date:  2020-07-06       Impact factor: 4.096

8.  Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.

Authors:  Nicholas J Short; Guillermo Montalban-Bravo; Hyunsoo Hwang; Jing Ning; Miguel J Franquiz; Rashmi Kanagal-Shamanna; Keyur P Patel; Courtney D DiNardo; Farhad Ravandi; Guillermo Garcia-Manero; Koichi Takahashi; Marina Konopleva; Naval Daver; Ghayas C Issa; Michael Andreeff; Hagop Kantarjian; Tapan M Kadia
Journal:  Blood Adv       Date:  2020-11-24

9.  Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT.

Authors:  Yuho Najima; Daichi Sadato; Yuka Harada; Keisuke Oboki; Chizuko Hirama; Takashi Toya; Noriko Doki; Kyoko Haraguchi; Kota Yoshifuji; Megumi Akiyama; Kyoko Inamoto; Aiko Igarashi; Takeshi Kobayashi; Kazuhiko Kakihana; Yoshiki Okuyama; Hisashi Sakamaki; Hironori Harada; Kazuteru Ohashi
Journal:  Bone Marrow Transplant       Date:  2020-08-05       Impact factor: 5.483

Review 10.  Treatment Strategies for Therapy-related Acute Myeloid Leukemia.

Authors:  Prajwal Dhakal; Bimatshu Pyakuryal; Prasun Pudasainee; Venkat Rajasurya; Krishna Gundabolu; Vijaya Raj Bhatt
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.